RAF1
RAF proto-oncogene serine/threonine-protein kinase
As of the edition of 20 October 2026, RAF1 (RAF proto-oncogene serine/threonine-protein kinase, UniProt P04049) has 11 drugs tested at it and 15 companies on the list, 7 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P04049
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 79
- Disease areas
- Cancer; Digestive system; Urinary and reproductive; Pregnancy and women's health; Skin and connective tissue; Hormones; Blood and lymph; Lungs and airways
- Registered trials of its drugs
- 953
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 3 |
| Went quiet | 2 |
| Stopped | 3 |
| Total | 11 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Sorafenib | Marketed | Phase 4 | Ends 2027 |
| Regorafenib | Marketed | Phase 4 | Ends 2032 |
| Tovorafenib | Marketed | Phase 3 | Ends 2031 |
| Naporafenib | Active | Phase 3 | none listed |
| Belvarafenib | Active | Phase 2 | none listed |
| Brimarafenib | Stopped | Phase 2 | none listed |
| XL-281 | Went quiet | Phase 2 | none listed |
| ICO-007 | Stopped | Phase 2 | none listed |
| Arq-736 free acid | Went quiet | Phase 1 | none listed |
| Exarafenib | Active | Phase 1 | none listed |
| LY-3009120 | Stopped | Phase 1 | none listed |
11 of 11 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 7 |
| Route B | 2 |
| Engaged | 5 |
| Undetermined | 1 |
| Total on the list | 15 |
| Company | Route |
|---|---|
| Merck KGaA | Route A |
| MapKure | Route A |
| Eli Lilly | Route A |
The other 12 companies at RAF1
In the product15 companies in all; 12 are not named here, and no score is.
See the 15 companies at RAF1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.